Put companies on watchlist
RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - adhoc news (35 News)
Country: Germany · Primary market: Germany · EQS NID: 1466081
18 October 2022 01:55PM

RHÖN-KLINIKUM Aktiengesellschaft: Changes on the Board of Management


EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Personnel
RHÖN-KLINIKUM Aktiengesellschaft: Changes on the Board of Management

18-Oct-2022 / 13:55 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Bad Neustadt a. d. Saale, 18 October 2022

RHÖN-KLINIKUM AG: Changes on the Board of Management

The Chief Executive Officer of RHÖN-KLINIKUM AG, Dr. Christian Höftberger, asked the Chairman of the Supervisory Board of the company last week to terminate his contract ahead of schedule. Consequently, the Supervisory Board resolved today, in a meeting convened at short notice, to comply with this request. With this consensual step, both Dr. Christian Höftberger and the Supervisory Board would like to create room for new dynamics in the stalled negotiations between RHÖN-KLINIKUM AG and the State of Hesse on securing the future of the University Hospital Gießen and Marburg (UKGM) in the interests of the employees and all patients of UKGM.

As the new Chief Executive Officer of RHÖN-KLINIKUM AG, the Supervisory Board has appointed Prof. Dr. Tobias Kaltenbach, who will take office on 1 November 2022. In addition, the Supervisory Board has decided to reduce the size of the company's Board of Management to three members. Prof. Dr. Bernd Griewing will move in his function as CMO (Chief Medical Officer) to the position of a General Representative. As of 1 November 2022, the Board of Management will thus consist of Prof. Dr. Tobias Kaltenbach (CEO), Dr. Stefan Stranz (CFO) and Dr. Gunther K. Weiß (COO).


Contact:

 

RHÖN-KLINIKUM AG
Head of Investor Relations and Treasury
Julian Schmitt

T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com


 

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale


18-Oct-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1466081

 
End of Announcement EQS News Service

1466081  18-Oct-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1466081&application_name=news&site_id=boersengefluester_html
Visual performance / price development - RHÖN-KLINIKUM Aktiengesellschaft
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.